Indian generics maker selling finished-dose medicines mainly in the US and other regulated markets, plus emerging markets and tenders.
Indian generics maker selling finished-dose medicines mainly in the US and other regulated markets, plus emerging markets and tenders.
Sells ready-to-use generic medicines, with the US the largest market, and also supplies other regulated, growth and institutional markets through tenders. In 2025 it split off its contract-manufacturing and soft-gel business into the separately listed OneSource Specialty Pharma, leaving a leaner generics business.
In one line: A niche soft-gel/regulated-market generics exporter.
Moat: narrow (regulatory licence, process know-how). Approved generic filings and regulator-inspected plants; crowded field with many similar generics makers.
Headquarters: Bengaluru, India · Founded: 1990 · Employees: 5,394
Size Strides Pharma Science (STAR.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $946M, the 622nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹958.10 on 18 Nov 2026.
Performance Over six months the shares fell 16.9%, against -20.3% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 11.3% over the last twelve months (peer median -4.4%); the operating margin is 14.2% (peer median 8.8%).
Valuation It trades at 15.9× forward earnings against a peer median of 24.5× (3rd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.0 points below its cost of capital (12.5% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹52.1B | ₹47.8B | ₹44.8B | ₹38.3B | ₹36.7B |
| Revenue growth | — | +7% | +17% | +4% | — |
| Gross profit | ₹19.1B | ₹13.6B | ₹11.8B | ₹8.51B | ₹8.05B |
| EBITDA | ₹9.56B | ₹7.69B | ₹7.10B | ₹5.15B | ₹3.66B |
| Net income | ₹6.17B | ₹5.56B | ₹4.05B | -₹1.20B | -₹2.21B |
| Free cash flow | n/a | ₹1.21B | ₹2.15B | ₹3.06B | -₹2.68B |
| Capital expenditure | n/a | ₹4.18B | ₹2.42B | ₹1.18B | ₹949M |
| Total debt | ₹19.0B | ₹17.6B | ₹18.8B | ₹25.2B | ₹30.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Strides Pharma Science STAR.NS | $946M | -17% | +11% | 14% | 15.9× | 17.6% |
| Aurobindo Pharma AUROPHARMA.NS | $11.0B | +19% | +14% | 15% | 22.3× | 21.1% |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% |
| Zydus Lifesciences ZYDUSLIFE.NS | $12.8B | +18% | +24% | 17% | 30.0× | n/a |
| Granules India GRANULES.NS | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STAR.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.9% | -9.1% | 9th highest of 21 |
| 6-month return | -16.9% | -20.3% | 10th highest of 21 |
| Distance from 52-week high | -24.0% | -46.9% | 5th highest of 21 |
| Revenue growth (TTM) | +11.3% | -4.4% | 8th highest of 18 |
| Operating margin | 14.2% | 8.8% | 6th highest of 18 |
| Forward P/E | 15.9× | 24.5× | 3rd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 17.6% | 7.1% | 2nd most demanding of 11 |
| Growth delivered (Del g) | +7.8% | +7.1% | 6th highest of 11 |
| Hurdle (Req g minus delivered) | +9.8 pp | -0.5 pp | 4th most demanding of 11 |
| ROIC minus cost of capital | -2.0 pp | -2.0 pp | 8th lowest of 16 |
| EV / EBITDA | 11.1× | 15.9× | 3rd cheapest of 7 |
| Net debt / EBITDA | 1.8× | 1.9× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | n/a | 10.3% | -13.7% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | n/a | n/a | n/a |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 50.2× | -10.2% | +18.1% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 22.9× | 9.1% | +13.4% |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 9.8× | -3.7% | +13.8% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | n/a | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |